Bank of America’s Acceleron Pharma XLRN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q4 | – | Sell |
-133,738
| Closed | -$23M | – | 9013 |
|
|
2021
Q3 | $23M | Buy |
133,738
+30,188
| +29% | +$3.95M | ﹤0.01% | 2051 |
|
|
2021
Q2 | $13M | Buy |
103,550
+9,664
| +10% | +$1.22M | ﹤0.01% | 2564 |
|
|
2021
Q1 | $12.7M | Sell |
93,886
-18,850
| -17% | -$2.43M | ﹤0.01% | 2486 |
|
|
2020
Q4 | $14.4M | Sell |
112,736
-288
| -0.3% | -$33.8K | ﹤0.01% | 2187 |
|
|
2020
Q3 | $12.7M | Buy |
113,024
+184
| +0.2% | +$18.3K | ﹤0.01% | 2087 |
|
|
2020
Q2 | $10.8M | Buy |
112,840
+25,798
| +30% | +$2.49M | ﹤0.01% | 2155 |
|
|
2020
Q1 | $7.82M | Sell |
87,042
-33,096
| -28% | -$2.57M | ﹤0.01% | 2269 |
|
|
2019
Q4 | $6.37M | Buy |
120,138
+37,911
| +46% | +$1.73M | ﹤0.01% | 3011 |
|
|
2019
Q3 | $3.25M | Sell |
82,227
-22,253
| -21% | -$965K | ﹤0.01% | 3605 |
|
|
2019
Q2 | $4.29M | Sell |
104,480
-21,540
| -17% | -$892K | ﹤0.01% | 3367 |
|
|
2019
Q1 | $5.87M | Buy |
126,020
+75,811
| +151% | +$3.33M | ﹤0.01% | 3013 |
|
|
2018
Q4 | $2.19M | Buy |
50,209
+6,366
| +15% | +$318K | ﹤0.01% | 3768 |
|
|
2018
Q3 | $2.51M | Sell |
43,843
-39,398
| -47% | -$1.94M | ﹤0.01% | 3804 |
|
|
2018
Q2 | $4.04M | Buy |
83,241
+26,046
| +46% | +$949K | ﹤0.01% | 3365 |
|
|
2018
Q1 | $2.24M | Buy |
57,195
+6,107
| +12% | +$260K | ﹤0.01% | 3795 |
|
|
2017
Q4 | $2.17M | Sell |
51,088
-46,380
| -48% | -$1.74M | ﹤0.01% | 3876 |
|
|
2017
Q3 | $3.64M | Buy |
97,468
+19,162
| +24% | +$665K | ﹤0.01% | 3467 |
|
|
2017
Q2 | $2.38M | Sell |
78,306
-13,002
| -14% | -$377K | ﹤0.01% | 3728 |
|
|
2017
Q1 | $2.42M | Buy |
91,308
+21,928
| +32% | +$578K | ﹤0.01% | 3708 |
|
|
2016
Q4 | $1.77M | Buy |
69,380
+25,229
| +57% | +$799K | ﹤0.01% | 3868 |
|
|
2016
Q3 | $1.6M | Sell |
44,151
-2,174
| -5% | -$72K | ﹤0.01% | 3818 |
|
|
2016
Q2 | $1.57M | Buy |
46,325
+1,878
| +4% | +$61.1K | ﹤0.01% | 3833 |
|
|
2016
Q1 | $1.17M | Sell |
44,447
-5,882
| -12% | -$171K | ﹤0.01% | 4000 |
|
|
2015
Q4 | $2.45M | Buy |
50,329
+48,921
| +3,475% | +$1.76M | ﹤0.01% | 3618 |
|
|
2015
Q3 | $35K | Sell |
1,408
-1,723
| -55% | -$51.8K | ﹤0.01% | 6110 |
|
|
2015
Q2 | $99K | Buy |
3,131
+1,985
| +173% | +$64.1K | ﹤0.01% | 5593 |
|
|
2015
Q1 | $44K | Buy |
1,146
+146
| +15% | +$5.81K | ﹤0.01% | 5721 |
|
|
2014
Q4 | $39K | Sell |
1,000
-174
| -15% | -$6.06K | ﹤0.01% | 6481 |
|
|
2014
Q3 | $36K | Sell |
1,174
-99
| -8% | -$2.79K | ﹤0.01% | 6731 |
|
|
2014
Q2 | $43K | Buy |
1,273
+1,259
| +8,993% | +$42.1K | ﹤0.01% | 6760 |
|
|
2014
Q1 | $0 | Buy |
+14
| New | +$632 | ﹤0.01% | 8206 |
|
Bank of America's XLRN Position: Q4 2021 in Review
Bank of America sold out of Acceleron Pharma (XLRN) in Q4 2021, closing a stake of 133,738 shares — an estimated $23M sold.
Bank of America first reported a position in XLRN in Q1 2014 and held it in 31 quarters. The position peaked at $23M in Q3 2021. 1 fund tracked by Wall St. Rank holds XLRN as of Q4 2021.
- Bank of America reported no remaining Acceleron Pharma position as of Q4 2021 after selling out during the quarter.
- Bank of America sold 133,738 Acceleron Pharma shares in Q4 2021, an estimated $23M.
- Bank of America first reported a position in Acceleron Pharma in Q1 2014 and held it in 31 quarters.
- Bank of America's Acceleron Pharma position peaked at $23M in Q3 2021.
- 1 fund tracked by Wall St. Rank held Acceleron Pharma as of Q4 2021.
Based on Bank of America's 13F filing for Q4 2021, filed 8 Feb 2022.